Get the Daily Brief
Latest Biotech News
Lyme vaccine shows strong efficacy: Pfizer, Valneva vow regulatory push
Pfizer and Valneva said their Phase 3 Lyme disease vaccine reduced cases by roughly 70–73% but missed the trial’s pre-specified statistical threshold. The companies acknowledged...
Insmed eyes front-line expansion after Arikayce late‑stage win
Insmed reported a Phase 3 victory for Arikayce in treatment‑naïve patients with Mycobacterium avium complex (MAC) lung infection, meeting the trial’s primary goals and showing improved respiratory...
Apogee’s long‑acting eczema drug promises less frequent dosing — rivals in sight
Apogee Therapeutics reported mid‑stage maintenance data showing its anti‑IL‑13 candidate induced durable skin and itch relief with far less frequent injections than current biologics. In the Phase...
Novartis buys Pikavation for up to $3B — bolsters PI3Kα cancer push
Novartis agreed to acquire Pikavation Therapeutics for up to $3 billion to add SNV4818, a mutant‑selective PI3Kα inhibitor, to its oncology pipeline. Novartis said SNV4818 aims to selectively...
Sanofi inks $1.2B deal for Kali trispecific — $180M upfront signals renewed T‑cell bet
Sanofi struck a partnership to license a Phase 1‑stage trispecific T‑cell engager from Kali Therapeutics, paying $180 million upfront and structuring the broader pact at up to $1.2 billion. The...
Crossbow closes $77M Series B to advance T‑cell engager for myeloid malignancies
Crossbow Therapeutics raised $77 million in a Series B round to advance its T‑Bolt platform and lead candidate CBX‑250, a T‑cell engager targeting relapsed or refractory myeloid malignancies. CEO...
Gates Foundation funds Tessera to pursue scalable genetic approaches toward HIV cure
Tessera Therapeutics received a grant from the Bill & Melinda Gates Foundation to support early‑stage work on genetic strategies aimed at a scalable cure for HIV. Tessera will use the funding to...
BIO board member warns Congress: China’s trial speed gives biotech advantage
Dr. Jacob Becraft, a BIO Board member and CEO of Strand Therapeutics, told the House Select Committee on China that China’s accelerated pathway to first‑in‑human trials is creating a competitive...
Varseta‑M data jolt CytomX shares: 32% ORR ignites volatile trading
CytomX released dose‑expansion data showing varsetatug masetecan (varseta‑M), an EpCAM‑targeting masked ADC, produced a 32% overall response rate and median progression‑free survival of 7.1 months...
WuXi AppTec shifts revenue mix toward US amid military‑link scrutiny
WuXi AppTec’s recent disclosure highlighted increasing revenue dependence on U.S. business as the contract research and manufacturing organization navigates investor concern about alleged ties to...
Aurinia boardroom coup — Kevin Tang ousts CEO and C-suite
Kevin Tang, an activist biotech investor, has consolidated control of Aurinia Pharmaceuticals and replaced the CEO and senior management, according to a securities filing. The filing shows Tang...
Zegfrovy beats chemo: Dizal posts Phase 3 first-line lung cancer win
Dizal reported Phase 3 data showing its drug Zegfrovy improved progression‑free survival versus chemotherapy in first‑line non‑small cell lung cancer (NSCLC) patients. The readout positions...
Lyme vaccine shows 73% efficacy... misses statistical threshold
Pfizer and Valneva reported that their Lyme disease vaccine reduced cases by roughly 73% in a large Phase 3 trial but failed to meet the trial’s pre‑specified statistical threshold because the...
Diasorin commits €10M to US launch — pivots China strategy, shutters German plant
Diasorin said it will invest about €10 million to commercialize its Liaison Nes point‑of‑care PCR platform in the U.S., building a 30‑person sales force and partnering with Thermo Fisher and...
Congress hearing: BIO board member says China speeds trials, threatens US lead
Dr. Jacob Becraft, CEO of Strand Therapeutics and a member of the BIO board, told the House Select Committee on China that China’s biotech ecosystem has accelerated clinical trial...
Apogee’s long‑acting eczema drug shows durable control with infrequent dosing
Apogee Therapeutics released Phase 2 maintenance data showing its anti‑IL‑13 candidate zumilokibart maintained EASI‑75 skin responses with far less frequent dosing: 75% of patients on quarterly...
Insmed’s Arikayce wins late‑stage trial — eyes earlier use in MAC lung disease
Insmed announced a Phase 3 win showing that adding Arikayce to standard therapy improved respiratory symptoms and culture conversion in patients with newly diagnosed Mycobacterium avium complex...
Sanofi returns to T‑cell engagers with $1.2B pact for phase‑1 trispecific
Sanofi struck a deal to acquire rights to a phase‑1 trispecific T‑cell engager from Kali Therapeutics, providing $180 million upfront as part of a broader agreement that can reach roughly $1.2...
Crossbow raises $77M Series B — funds lead Phase I for CBX‑250
Crossbow Therapeutics closed a $77 million Series B to advance its T‑Bolt platform and support a Phase I trial of CBX‑250, a novel T‑cell engager targeting relapsed and refractory myeloid...
Novartis agrees up to $3B acquisition — picks up mutant‑selective PI3Kα asset SNV4818
Novartis agreed to acquire Pikavation Therapeutics for up to $3 billion to obtain SNV4818, a pan‑mutant selective PI3Kα inhibitor in early clinical testing for HR+/HER2‑ metastatic breast cancer...